XTX Topco’s Propanc Biopharma PPCB Stock Holding History

XTX Topco’s Portfolio PPCB Stock Details PPCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.28K	Sell	484 -401	-45%	-$2.38K	﹤0.01%	3771
2025 Q4	$11.9K	Buy	+885	New	+$24.5K	﹤0.01%	3158

Other funds holding PPCB

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

SCA

Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return

XTX Topco's PPCB Position: Q1 2026 in Review

XTX Topco reduced its Propanc Biopharma (PPCB) stake by 45% in Q1 2026, selling an estimated $2.38K and leaving 484 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #3771.

XTX Topco first reported a position in PPCB in Q4 2025 and has held it in 2 quarters since. The position peaked at $11.9K in Q4 2025. 6 funds tracked by Wall St. Rank hold PPCB as of Q1 2026.

XTX Topco held 484 shares of Propanc Biopharma worth $1.28K as of Q1 2026.
XTX Topco sold 401 Propanc Biopharma shares in Q1 2026, an estimated $2.38K.
Propanc Biopharma made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3771 holding.
XTX Topco first reported a position in Propanc Biopharma in Q4 2025 and has held it in 2 quarters since.
XTX Topco's Propanc Biopharma position peaked at $11.9K in Q4 2025.
6 funds tracked by Wall St. Rank held Propanc Biopharma as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.